63 related articles for article (PubMed ID: 18193578)
1. [A short-term effect of lovastatin on lipoprotein metabolism in patients with cerebrovascular lesions concomitant with diabetes mellitus II type].
Bozhko GKh; Sokolik VV; Chursina VS; Pertseva TG
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Suppl 17():47-51. PubMed ID: 18193578
[TBL] [Abstract][Full Text] [Related]
2. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
[TBL] [Abstract][Full Text] [Related]
3. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus.
Safaei H; Janghorbani M; Aminorroaya A; Amini M
Acta Diabetol; 2007 Jun; 44(2):76-82. PubMed ID: 17530471
[TBL] [Abstract][Full Text] [Related]
4. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
5. Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy.
Nezami N; Safa J; Salari B; Ghorashi S; Khosraviani K; Davari-Farid S; Hashemi-Aghdam Y; Nargabad ON; Tabrizi JS
Nucleosides Nucleotides Nucleic Acids; 2012 Apr; 31(4):353-63. PubMed ID: 22444196
[TBL] [Abstract][Full Text] [Related]
6. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy.
Nezami N; Safa J; Eftekhar-Sadat AT; Salari B; Ghorashi S; Sakhaee K; Khosraviani K
Clin Biochem; 2010 Nov; 43(16-17):1294-9. PubMed ID: 20727867
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
Gholamin S; Razavi SM; Taghavi-Garmestani SM; Ghorbanihaghjo A; Rashtchizadeh N; Safa J; Vatankhah AM; Azizi T; Argani H
Iran J Kidney Dis; 2014 May; 8(3):201-6. PubMed ID: 24878942
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Richter WO; Jacob BG; Schwandt P
Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus.
Tavintharan S; Lim SC; Chan YH; Sum CF
Diabetes Obes Metab; 2007 Jan; 9(1):81-6. PubMed ID: 17199722
[TBL] [Abstract][Full Text] [Related]
10. Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome.
Wanner C; Böhler J; Eckardt HG; Wieland H; Schollmeyer P
Clin Nephrol; 1994 Mar; 41(3):138-43. PubMed ID: 8187355
[TBL] [Abstract][Full Text] [Related]
11. Re: Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
Ahmadi F; Mohebi-Nejad A
Iran J Kidney Dis; 2014 Jul; 8(4):344-5. PubMed ID: 25001144
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia.
Clauss SB; Holmes KW; Hopkins P; Stein E; Cho M; Tate A; Johnson-Levonas AO; Kwiterovich PO
Pediatrics; 2005 Sep; 116(3):682-8. PubMed ID: 16140708
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy.
Rashtchizadeh N; Argani H; Ghorbanihaghjo A; Nezami N; Safa J; Montazer-Saheb S
Iran J Kidney Dis; 2009 Apr; 3(2):93-8. PubMed ID: 19395785
[TBL] [Abstract][Full Text] [Related]
14. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
Farmer JA; Washington LC; Jones PH; Shapiro DR; Gotto AM; Mantell G
Clin Ther; 1992; 14(5):708-17. PubMed ID: 1468089
[TBL] [Abstract][Full Text] [Related]
16. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
[TBL] [Abstract][Full Text] [Related]
17. Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis.
Mihaila RG; Nedelcu L; Fratila O; Rezi EC; Domnariu C; Deac M
Hepatogastroenterology; 2009; 56(93):1117-21. PubMed ID: 19760953
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.
Chan DC; Watts GF
Expert Opin Pharmacother; 2011 Jan; 12(1):13-30. PubMed ID: 20629587
[TBL] [Abstract][Full Text] [Related]
19. [Hypothyroidism and lovastatin-induced myositis].
Rodríguez Framil M; Martínez Rey C; Alende Sixto MR; Torre Carballada JA
An Med Interna; 2005 May; 22(5):252-3. PubMed ID: 16089017
[No Abstract] [Full Text] [Related]
20. A novel concept to preserve the beneficial effects of hormone replacement therapy in bilaterally female ovariectomized rats: role of lovastatin therapy.
El-Swefy SE; Asker ME; Ali SI; Mohammed HE
Pharmacol Res; 2002 Mar; 45(3):167-73. PubMed ID: 11884211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
